Suppr超能文献

相似文献

1
Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.
Pharmacol Rev. 2011 Dec;63(4):1001-19. doi: 10.1124/pr.111.004598. Epub 2011 Aug 26.
2
Effector antagonism by the regulators of G protein signalling (RGS) proteins causes desensitization of mu-opioid receptors in the CNS.
Psychopharmacology (Berl). 2005 Jun;180(1):1-11. doi: 10.1007/s00213-005-2248-9. Epub 2005 Apr 14.
4
[Development of opioid tolerance -- molecular mechanisms and clinical consequences].
Anasthesiol Intensivmed Notfallmed Schmerzther. 2003 Jan;38(1):14-26. doi: 10.1055/s-2003-36558.
7
The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats.
Drug Alcohol Depend. 2018 Nov 1;192:158-162. doi: 10.1016/j.drugalcdep.2018.08.002. Epub 2018 Sep 18.
8
Spinal Opioid Tolerance Depends upon Platelet-Derived Growth Factor Receptor- Signaling, Not -Opioid Receptor Internalization.
Mol Pharmacol. 2020 Oct;98(4):487-496. doi: 10.1124/mol.120.119552. Epub 2020 Jul 28.
9
Clinical opioids differentially induce co-internalization of μ- and δ-opioid receptors.
Mol Pain. 2018 Jan-Dec;14:1744806918769492. doi: 10.1177/1744806918769492. Epub 2018 Mar 27.
10
Change in functional selectivity of morphine with the development of antinociceptive tolerance.
Br J Pharmacol. 2015 Jan;172(2):549-61. doi: 10.1111/bph.12703. Epub 2014 Jul 1.

引用本文的文献

1
GPER Enhances Chronic Burn Pain via PKC-Mediated Mu-Opioid Receptor Phosphorylation in the Rostral Ventromedial Medulla.
J Pain Res. 2025 Aug 2;18:3859-3878. doi: 10.2147/JPR.S529103. eCollection 2025.
2
Overview and Prospects of the Clinical Application of Oliceridine.
Drug Des Devel Ther. 2025 Jun 26;19:5415-5430. doi: 10.2147/DDDT.S525471. eCollection 2025.
3
Fentanyl-Antibody Interaction as a Novel Strategy against Opiates and Opioids Abuse.
J Med Chem. 2025 Apr 24;68(8):7866-7888. doi: 10.1021/acs.jmedchem.4c02860. Epub 2025 Apr 3.
4
Biased Opioid Receptor Agonists: Balancing Analgesic Efficacy and Side-Effect Profiles.
Int J Mol Sci. 2025 Feb 21;26(5):1862. doi: 10.3390/ijms26051862.
6
Examining the Severity and Progression of Illicitly Manufactured Fentanyl Withdrawal: A Quasi-experimental Comparison.
J Addict Med. 2025;19(2):172-178. doi: 10.1097/ADM.0000000000001395. Epub 2024 Nov 26.
7
Ketamine and Major Ketamine Metabolites Function as Allosteric Modulators of Opioid Receptors.
Mol Pharmacol. 2024 Oct 17;106(5):240-252. doi: 10.1124/molpharm.124.000947.
8
G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery.
Signal Transduct Target Ther. 2024 Apr 10;9(1):88. doi: 10.1038/s41392-024-01803-6.
10
Development of tolerance to chemokine receptor antagonists: current paradigms and the need for further investigation.
Front Immunol. 2023 Jul 28;14:1184014. doi: 10.3389/fimmu.2023.1184014. eCollection 2023.

本文引用的文献

1
Recovery from mu-opioid receptor desensitization after chronic treatment with morphine and methadone.
J Neurosci. 2011 Mar 23;31(12):4434-43. doi: 10.1523/JNEUROSCI.4874-10.2011.
4
Protein kinase C-mediated phosphorylation of the μ-opioid receptor and its effects on receptor signaling.
Mol Pharmacol. 2011 Apr;79(4):768-75. doi: 10.1124/mol.110.069096. Epub 2011 Jan 6.
5
Functional selectivity and biased receptor signaling.
J Pharmacol Exp Ther. 2011 Feb;336(2):296-302. doi: 10.1124/jpet.110.173948. Epub 2010 Oct 28.
7
Biased agonism.
F1000 Biol Rep. 2009 Nov 26;1:87. doi: 10.3410/B1-87.
9
The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics.
Neuropharmacology. 2011 Jan;60(1):58-65. doi: 10.1016/j.neuropharm.2010.08.003. Epub 2010 Aug 14.
10
Pain market.
Nat Rev Drug Discov. 2010 Aug;9(8):589-90. doi: 10.1038/nrd3226. Epub 2010 Jul 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验